ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,220.98
0.69%
S&P 500
5,222.68
0.16%
Dow Jones
39,512.84
0.32%
US Dollar vs Yen
155.775
0.00%
Brent Oil
82.585
0.00%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) ニュース

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:PRLD
日付受信時刻ニュースソース見出しコード企業名
2024/05/0920 : 01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
2024/05/0913 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
2024/05/0720 : 20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
2024/05/0720 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
2024/05/0720 : 01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
2024/05/0705 : 24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
2024/04/1005 : 35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0606 : 45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0508 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0508 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0508 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0508 : 01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0507 : 59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2024/03/0106 : 05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
2024/02/1607 : 22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
2024/02/1606 : 22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
2024/02/1606 : 05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
2024/02/1306 : 26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
2024/01/0907 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2023/12/1123 : 34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
2023/12/1123 : 17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
2023/11/0205 : 37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
2023/11/0205 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
2023/11/0205 : 10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
2023/11/0205 : 05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
2023/11/0205 : 05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
2023/10/1501 : 30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
2023/10/0622 : 07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
2023/08/2921 : 30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
2023/08/0321 : 14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PRLD

最近閲覧した銘柄

CCOM
US100
US Tech 100
NASDAQ
AMZN
Amazon.com
NYSE
CVX
Chevron
NYSE
MCD
McDonalds
NYSE
NKE
Nike
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
FX
USDJPY
US Dollar vs Yen
USOTC
ADDYY
Adidas (QX)
USOTC
RHHBY
Roche (QX)
COIN
SOLUSD
Solana
CCOM
SILVER
SILVER
USOTC
BASFY
BASF (QX)
NYSE
KO
Coca Cola
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有